MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.53) per share for the quarter.
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.09). On average, analysts expect MoonLake Immunotherapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
MoonLake Immunotherapeutics Price Performance
Shares of NASDAQ:MLTX traded down $0.01 on Friday, hitting $41.76. 302,843 shares of the company's stock were exchanged, compared to its average volume of 439,783. The stock has a market capitalization of $2.67 billion, a price-to-earnings ratio of -32.37 and a beta of 1.28. MoonLake Immunotherapeutics has a 12 month low of $37.55 and a 12 month high of $58.26. The business's 50 day simple moving average is $46.49 and its two-hundred day simple moving average is $48.94.
Analysts Set New Price Targets
Several research firms have issued reports on MLTX. HC Wainwright reissued a "buy" rating and issued a $100.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Thursday. The Goldman Sachs Group lowered their price target on MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating for the company in a report on Thursday. Needham & Company LLC raised their price objective on MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the stock a "buy" rating in a report on Thursday. Finally, Wedbush reaffirmed an "outperform" rating and set a $73.00 target price (down from $92.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, MoonLake Immunotherapeutics currently has an average rating of "Buy" and an average price target of $83.20.
Check Out Our Latest Stock Report on MoonLake Immunotherapeutics
About MoonLake Immunotherapeutics
(
Get Free Report)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Featured Stories
Before you consider MoonLake Immunotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MoonLake Immunotherapeutics wasn't on the list.
While MoonLake Immunotherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
